HeartBeam (Nasdaq:BEAT) announced today that it entered into a strategic collaboration with the Icahn School of Medicine at Mount Sinai.

Myocardial ischemia, the primary driver of heart attacks, remains the leading cause of death and disability worldwide. Delays in diagnosis directly correlate with increased myocardial necrosis, higher ...

Chronic disease care depends on consistent, reliable, and structured monitoring. Traditional testing methods can sometimes be inconvenient and time-consuming, affecting adherence. Non-invasive ...

HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to ...

According to the latest research study published by Vyansa Intelligence, the Cardiovascular Devices Market in the United States is projected ...

ARGENTIC aims to develop a sovereign, trustworthy, and energy-efficient European ecosystem for agentic AI — that is, AI ...

HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New ...

Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk ・Combines Mount Sinai’s world-class AI and ...

From the Oura Ring to the Apple Watch to the Google Pixel — here's what the science really says about the accuracy of their health data ...

The architecture of a multimodal system depends on the coordination of diverse hardware and software components into a single ...

Increasing Demand for ECMO Systems, Portable Devices, and Pediatric Cardiac Support, Along with Expanding Hospital Infrastructure and Smart Monitoring Innovations, Fuel Market Growth.Austin, United ...